Brief: Theravance Biopharma Inc - Co And Mylan Settle With Cipla Over Yupelri Inhalation Solution - SEC Filing
20/08/2025 13:15
Theravance Biopharma Inc TBPH.O: THERAVANCE BIOPHARMA INC - CO AND MYLAN SETTLE WITH CIPLA OVER YUPELRI INHALATION SOLUTION - SEC FILING THERAVANCE BIOPHARMA- CO, MYLAN GRANTED CIPLA LICENSE TO MANUFACTURE & MARKET GENERIC VERSION OF YUPELRI IN US ON/AFTER APRIL 23, 2039 Source text: [ID:n0001104659-25-080470] Further company coverage: TBPH.O
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy